Core Insights - Health 160 International Limited has been included in the Hang Seng Composite Index, marking a significant milestone since its listing on the Hong Kong Stock Exchange in September 2025 [1][2] - The inclusion is expected to enhance the company's liquidity and valuation as it will attract investment from index funds [1][2] Group 1: Index Inclusion and Market Impact - The inclusion in the Hang Seng Composite Index will take effect after the market closes on March 6, 2026, and will officially start on March 9, 2026 [1] - Health 160's entry into multiple indices, including the Hang Seng Healthcare Index and the Hang Seng Stock Connect indices, is anticipated to broaden its investment appeal to institutional investors [1][2] Group 2: Access to Mainland Investors - Being part of the Hang Seng Composite Index is a crucial prerequisite for inclusion in the Stock Connect program, which allows mainland investors to directly invest in Health 160 [3] - This access to mainland capital is expected to provide a stable influx of funds, improving the company's shareholder structure and stock liquidity [3] Group 3: Business Model and Growth Potential - Health 160 operates a dual-driven business model combining "pharmaceutical health product sales" and "digital healthcare solutions," positioning it as a leader in China's digital healthcare sector [4] - The company has established a vast network, connecting over 44,800 healthcare institutions and 5.69 million registered users, creating a significant competitive barrier [4] Group 4: Financial Outlook and Analyst Ratings - Analysts have expressed optimism regarding Health 160's long-term value, with several brokerage firms initiating coverage and issuing "buy" ratings [5] - Target prices from analysts suggest substantial upside potential, with estimates indicating a nearly 70% increase from current stock prices [5]

Core Viewpoint - The Hang Seng Index Company announced the quarterly review results for the Hang Seng Index series, with Health 160 (02656) being included in the Hang Seng Composite Index, effective March 9, 2026 [1] Group 1: Company Overview - Health 160 is an experienced Chinese pharmaceutical and health products wholesaler and a leading provider of integrated digital healthcare services [1] - The company offers a variety of pharmaceutical health products and comprehensive digital healthcare solutions [1] - Health 160 operates an online healthcare service platform that connects various participants in the healthcare industry [1] Group 2: Market Impact - The inclusion of Health 160 in the Hang Seng Composite Index may lead to its potential addition to the Stock Connect program, as it meets criteria such as market capitalization, liquidity, and listing duration [1] - As of March 31, 2025, Health 160's platform has connected over 44,600 healthcare institutions since its establishment [1]

Core Viewpoint - The Hang Seng Index Company announced the inclusion of Health 160 (02656) in the Hang Seng Composite Index, effective March 9, 2026, following a quarterly review [1] Group 1: Company Overview - Health 160 is an experienced wholesaler of Chinese pharmaceutical and health products, as well as a leading provider of integrated digital healthcare services [1] - The company offers a variety of pharmaceutical health products and comprehensive digital healthcare solutions [1] - Health 160 operates an online healthcare service platform that connects various participants in the healthcare industry, having connected over 44,600 healthcare institutions since its establishment [1] Group 2: Market Impact - The inclusion of Health 160 in the Hang Seng Composite Index may lead to its potential addition to the Stock Connect program, as it meets criteria such as market capitalization, liquidity, and listing duration [1]

去年12月22日，华芢生物-B(02396)正式挂牌上市。作为一只采用"机制B"发行方案IPO上市的标的，华芢生物首挂当日 表现不佳，报收27.00港元，跌幅达到29.32%。由于自带"港股PDGF第一股"光环，这家公司此前被不少打新投资者视 为年末的"创新药大肉"之一。挂牌首日如此表现显然低于不少投资者预期。 从发行方案来看，华芢生物在发行上采用了"机制B+无基石"方式，倚赖机构投资者作"市场锚定"。如今看来，该方案 对于一家基本面有待提高的未盈利18A而言或许有些激进，但对于当时的华芢生物来说，只是"踩着石头过河"，而这 条路正是健康160踩出来的。 靠"机制B+无基石"博进港股通 2月11日，健康160(02656)股价在低开震荡约1个小时后突然大幅跳水，半个小时内，公司股价从约90港元跳水跌至最 低55港元，盘中股价振幅接近40%，最终公司当日收跌30.73%。公司股价由此回吐年内多数涨幅，总市值一度跌穿 200亿港元。 其实对比华芢生物和健康160的IPO发行方案，投资者不难看出二者间的相似之处。 自去年8月港交所港股发布IPO新规以来，不少企业把公开配售压到10%的下限，"人为制造"极致缩量的流通 ...

2月11日，健康160(02656)股价在低开震荡约1个小时后突然大幅跳水，半个小时内，公司股价从约90港元跳水跌至最 低55港元，盘中股价振幅接近40%，最终公司当日收跌30.73%。公司股价由此回吐年内多数涨幅，总市值一度跌穿 200亿港元。 从发行方案来看，华芢生物在发行上采用了"机制B+无基石"方式，倚赖机构投资者作"市场锚定"。如今看来，该方案 对于一家基本面有待提高的未盈利18A而言或许有些激进，但对于当时的华芢生物来说，只是"踩着石头过河"，而这 条路正是健康160踩出来的。 靠"机制B+无基石"博进港股通 其实对比华芢生物和健康160的IPO发行方案，投资者不难看出二者间的相似之处。 自去年8月港交所港股发布IPO新规以来，不少企业把公开配售压到10%的下限，"人为制造"极致缩量的流通盘，并形 成以机构、基石和锚定投资者为主的发行格局，为公司上市开局"保价护航"。据智通财经APP了解，在选择"机制B"的 基础上，两家公司均选择了"无基石"方案，仅设有"绿鞋"机制。如此一来，其高达90%的国际配售比例在缺乏基石锁 仓情况下，基本只能倚赖机构投资者作"市场锚定"。 根据发行计划，健康160全球发售 ...

Core Viewpoint - Health 160 has been included in the short-selling designated securities list by the Hong Kong Stock Exchange, which is a routine adjustment based on market liquidity and market capitalization, and does not reflect the company's fundamental performance or operational status [1][2] Group 1: Market Reaction and Stock Performance - Following its inclusion in the short-selling list, Health 160's stock price experienced short-term fluctuations, primarily driven by market sentiment and investor misunderstanding of market rules, rather than a true reflection of the company's intrinsic value [2] - Since the beginning of 2026, Health 160's stock has shown a steady upward trend, with a peak increase of 62.55%, closing at HKD 90.80 on February 10, 2026, with a total market capitalization of HKD 30.55 billion [2] Group 2: Company Growth and Future Outlook - Health 160 is accelerating its layout in the AI + healthcare sector, with multiple institutions raising their target prices, reflecting strong confidence in the company's growth prospects [2] - On February 5, Huasheng Securities raised Health 160's target price to HKD 150.15, indicating a potential upside of approximately 69.57%, and forecasts the company will achieve profitability by 2026 with a projected net profit of HKD 96 million [2] - Revenue growth rates are expected to increase significantly from 11.65% to 57.04% from 2025 to 2027, indicating an accelerating growth trend [2] Group 3: Competitive Position and Technological Advancements - As a leading player in China's digital healthcare sector, Health 160 has established a comprehensive digital healthcare ecosystem, differentiating itself from competitors like OpenEvidence by covering the entire patient journey with its AI health management system [3] - The company's AI applications have generated substantial economic value, with its OCR technology achieving an accuracy rate of 89%, significantly higher than the industry average [4] - Health 160's platform connects over 44,800 healthcare institutions, including 3,441 tertiary hospitals, and has registered 56.9 million personal users, creating a robust ecosystem that supports the application of AI technology [4] Group 4: Strategic Focus and Investor Communication - Health 160's inclusion in the short-selling list will not alter its development strategy or operational pace, as the company remains focused on deepening its digital healthcare ecosystem and enhancing the application of AI technology in the healthcare sector [4] - The company emphasizes the importance of investors maintaining a rational perspective on short-term market fluctuations and focusing on the company's fundamentals and long-term value [4]

Group 1 - The Hang Seng Index rose by 0.43%, gaining 116 points to close at 27,299 points, while the Hang Seng Tech Index increased by 1.10% [1] - Xiaomi Group-W (01810) saw a rise of over 4%, with the new generation SU7 expected to launch in April [1] - The first-day listing of Xian Dao Intelligent (00470) increased by 0.44%, while fishing company Lexin Outdoor (02720) surged by 33% on its second day of trading [1] - The Kintor Group (00148) and Kintor Laminates (01888) experienced gains of 5% and 14% respectively, driven by expected high growth in copper-clad laminate performance by 2025 [1] - The precious metals sector saw gains, with Wan Guo Gold Group (03939) rising over 9% to reach a new high, benefiting from increased gold prices [1] - Tungsten prices continued to rise, with tungsten oxide increasing by 20,000 yuan per ton and ammonium paratungstate rising by 10,000 yuan per ton, leading to a surge of over 12% for Jiaxin International Resources (03858) [1] - China Duty Free Group (01880) rose over 5% following a strong start to the Spring Festival travel season for duty-free shopping in Hainan [1] Group 2 - Gilead Sciences-B (01672) increased by over 6%, with plans to submit an IND for ASC36 oral tablets for obesity treatment to the FDA in the second quarter [2] - Jinli Permanent Magnet (06680) rose over 7% as rare earth prices continue to climb, with institutions predicting a dual increase in valuation and performance for the sector [3] - Mongol Mining (00975) surged over 11% as its BKH gold mine ramped up production and dividend restrictions were gradually lifted [4] - Semiconductor Manufacturing International Corporation (00981) fell by 3.63% post-earnings, with Goldman Sachs indicating that its first-quarter gross margin guidance was below expectations [5] - Health 160 (02656) plummeted by 33%, retracting most of its gains for the year, with its total market value briefly falling below 20 billion HKD [6]

Group 1 - Gold stocks continue to rise, with significant increases in companies such as WanGuo Gold Group (up 9.39%), Zijin Mining (up 3.5%), and Lingbao Gold (up 7.24%), driven by fluctuating gold prices and rising interest rate cut expectations [1][2] - Zijin Mining has approved a three-year production plan for major mineral products from 2026 to 2028, outlining clear production targets [1] - China Duty Free Group reported a 14.71% year-on-year increase in duty-free shopping amounts, totaling 11.585 billion yuan since the policy adjustment [1] Group 2 - Mongol Mining shares rose over 15% during trading, reflecting its transition from a single coking coal producer to a multi-mineral producer, including gold and copper [2] - Semiconductor manufacturer SMIC reported a 12.8% year-on-year increase in Q4 2025 revenue, reaching $2.489 billion, with a 60.7% increase in attributable profit [2] - Health 160 experienced a significant drop of nearly 40%, with its market value falling below 20 billion HKD, indicating a major reversal in its stock performance [2] Group 3 - Xiaomi Group shares increased nearly 5% following a live broadcast by its founder, emphasizing ongoing investments in technology and product development [3] - Zhizhu shares rose over 10% this week, with a cumulative increase exceeding 70%, driven by the launch of a new anonymous model by OpenRouter [3] - Jiantao Group stocks rose due to increased demand for high-end copper-clad laminates driven by AI computing power [3] Group 4 - Jaguar Uranium's stock opened over 35% higher on its debut in the US market but later fell by 23.25%, indicating volatility in its initial trading [4] - NIO shares rose 1.43% as the CEO highlighted significant achievements and future plans for profitability by 2026 [4] - Sohu reported a 6% year-on-year revenue increase in Q4 2025, with a notable reduction in losses compared to the previous year [4] Group 5 - Ferrari's Q4 2025 revenue reached €1.8 billion (approximately $2.14 billion), exceeding expectations, with a positive outlook for 2026 [5] - Philips reported a 1% year-on-year sales increase in Q4, with adjusted EBITA surpassing market expectations, particularly in its personal health segment [5]

Core Viewpoint - Health 160 (02656) experienced a significant decline of nearly 40%, retracting most of its gains for the year, with its market capitalization briefly falling below HKD 20 billion [1] Group 1: Company Overview - Health 160 is an experienced wholesale distributor of pharmaceutical and health products in China and a leading provider of integrated digital healthcare services [1] - The company offers a variety of pharmaceutical health products and comprehensive digital healthcare solutions [1] Group 2: Market Performance - As of the latest report, Health 160's stock price dropped by 32.1%, trading at HKD 61.65, with a trading volume of HKD 32.83 million [1] - The company went public on September 17, 2025, and is facing a significant unlock of restricted shares, with 267 million shares (79% of the circulating shares) set to be released on the same date [1]

Core Viewpoint - Health 160 (02656) experienced a significant decline of nearly 40%, retracting most of its gains for the year, with its market capitalization briefly falling below HKD 20 billion [1] Company Overview - Health 160 is an experienced wholesale distributor of pharmaceutical and health products in China and a leading provider of integrated digital healthcare services [1] - The company offers a variety of pharmaceutical health products and comprehensive digital health solutions [1] - As of March 31, 2025, Health 160's platform has connected over 44,600 healthcare institutions, including more than 14,400 hospitals and over 30,200 grassroots healthcare institutions [1] Market Activity - Health 160 was listed on September 17, 2025 [1] - According to previous reports, companies with high lock-up release market values may face stock price pressure before and after the release [1] - Health 160 is set to unlock 267 million shares on September 17, which represents 79% of its circulating shares [1]